indazoles has been researched along with Thyroid Neoplasms in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (10.00) | 29.6817 |
| 2010's | 31 (77.50) | 24.3611 |
| 2020's | 5 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bardet, S; Benisvy, D; Borson Chazot, F; Chougnet, CN; Dalban, C; de la Fouchardière, C; Digue, L; Do Cao, C; Gautier, J; Godbert, Y; Illouz, F; Lamartina, L; Leboulleux, S; Niccoli, P; Pérol, D; Schwartz, P; Wassermann, J; Zalzali, M; Zerdoud, S | 1 |
| Anderson, E; Bell, AC; Fan, D; Ganly, I; Groen, AH; Kang, JJ; Lee, NY; Leeman, JE; Lok, BH; Ma, J; McBride, S; Olsen, KS; Riaz, N; Shaha, AR; Sherman, EJ; Tsai, CJ | 1 |
| Cho, YK; Choi, MG; Huh, JH; Ihm, SH; Kang, JG; Kim, SH; Lee, SJ | 1 |
| E Schweppe, R; Espinoza, VL; Hicks, HM; LaBarbera, D; McKenna, LR; Pike, LA; Pozdeyev, N; Raeburn, CD; Reigan, P; Sams, SB | 1 |
| Aust, D; Folprecht, G; Fröhling, S; Glimm, H; Hanf, D; Heining, C; Herbst, F; Hutter, B; Jahn, A; Laaber, K; Nebelung, H; Richter, D; Uhrig, S | 1 |
| Anderson, LN; Chow, LQ; Doot, R; Failor, A; Mankoff, D; Pantel, A; Roth, M; Santana-Davila, R | 1 |
| Adrián, SG; Aller, J; Astorga, BG; Bohn, U; Cajal, TRY; Capdevila, J; Cillán, E; Duran-Poveda, M; Grande, E; Grau, JJ; Llopis, CZ; López-Alfonso, A; Manzano, JL; Martínez, JM; Matos, I; Palacios, N; Porras, I; Reig, Ò; Reina, JJ; Trigo, JM | 1 |
| García-Alemán, J; Mancha-Doblas, I; Molina-Vega, M; Sebastián-Ochoa, A; Tinahones-Madueño, F; Trigo-Pérez, JM | 1 |
| Kushnir, I; Merimsky, O; Soyfer, V | 1 |
| Beckham, TH; Brinkman, T; Fagin, JA; Groen, AH; Lee, NY; McBride, S; Riaz, N; Romesser, PB; Sabol, C; Sabra, M; Shaha, AR; Sherman, EJ; Spielsinger, D; Tsai, CJ; Tuttle, RM; Wong, RJ | 1 |
| Bauer, J; Grimm, D; Grosse, J; Infanger, M; Kopp, S; Krüger, M; Milling, RV; Wehland, M | 1 |
| Ahmed, S; Azad, NS; Ball, DW; Bishop, JA; Gocke, CD; Ha, Y; Karunsena, E; Kurzrock, R; Nelkin, BD; O'Connor, A; Parkinson, RM; Rudek, MA; Sharma, R; Sherman, SI; Subbiah, V; Zahurak, ML; Zinner, R | 1 |
| Abd Elmageed, ZY; Abdel-Mageed, AB; Kandil, E; Li, X; Ma, J; Mondal, D; Slakey, D; Tsumagari, K | 1 |
| Brabant, G; Burrows, N; Telfer, B; Williams, KJ | 1 |
| Bible, KC; Bieber, C; Burton, JK; Cher Goh, B; Erlichman, C; Fatourechi, V; Flynn, PJ; Harris, P; Hay, I; Isham, CR; Karlin, N; Maples, WJ; McIver, B; Menefee, ME; Molina, JR; Morris, JC; Rubin, J; Sideras, K; Smallridge, RC; Suman, VJ; Traynor, AM; Webster, KP | 1 |
| Bible, KC; Bossou, AR; Cradic, KW; Grebe, SK; Isham, CR; Milosevic, D; Netzel, BC | 1 |
| Agate, L; Boucher, A; Bycott, P; Chen, C; Cohen, EE; Ingrosso, A; Jarzab, B; Kane, MA; Kim, S; Licitra, L; Locati, LD; Ou, SH; Pithavala, YK; Qin, S; Wirth, LJ | 1 |
| Bagcchi, S | 1 |
| Bycott, P; Cohen, EE; Ingrosso, A; Kim, S; Pithavala, YK; Tortorici, M | 1 |
| Carcangiu, ML; Cohen, EE; Greco, A; Joseph, L; Khattri, A; Licitra, L; Lingen, MW; Locati, LD; Nagilla, M; Pelosi, G; Reddy, P; Schechter, RB; Seiwert, TY; Watson, S | 1 |
| Di Bella, S; Facchetti, R; Giannattasio, C; Giganti, MO; Maloberti, A; Mancia, G; Meani, P; Moreo, A; Musca, F; Pozzi, M; Ricotta, R; Sartore-Bianchi, A; Siena, S; Stucchi, M; Vallerio, P | 1 |
| Choi, MG; Ihm, SH; Kang, JG; Kim, CS; Kim, SH; Lee, SJ; Yoo, HJ | 1 |
| Ahmed, SR; Ball, DW; Bhan, S; Clark, DP; Jin, N; Nelkin, BD; Rosen, DM; Schayowitz, A; Xue, P | 1 |
| Covell, LL; Ganti, AK | 1 |
| Spector, M; Swiecicki, PL; Worden, FP | 1 |
| Brabant, G; Burrows, N; Eustace, A; Fitzmaurice, RJ; Hoang-Vu, C; Irlam, J; Resch, J; Rowling, EJ; Telfer, BA; Valentine, HR; West, CM; Williams, J; Williams, KJ | 1 |
| Camille, N; Dang, RP; Genden, EM; Le, VH; McFarland, D; Miles, BA; Misiukiewicz, KJ; Teng, MS | 1 |
| Bycott, P; Cohen, EE; Cohen, RB; Forastiere, AA; Kane, MA; Kies, MS; Kim, S; Liau, KF; Rosen, LS; Shalinsky, DR; Sherman, E; Tortorici, M; Vokes, EE; Worden, FP | 1 |
| Sherman, SI | 2 |
| Kelly, RJ; Rixe, O | 1 |
| Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
| Bible, KC; Burton, JK; Erlichman, C; Ivy, SP; Menefee, ME; Sideras, K | 1 |
| Bible, KC; Bieber, C; Burton, JK; Erlichman, C; Flynn, PJ; Goh, BC; Ivy, SP; Maples, WJ; McIver, B; Menefee, ME; Molina, JR; Morris, JC; Rubin, J; Sideras, K; Smallridge, RC; Suman, VJ; Tang, H; Traynor, AM; Webster, KP | 1 |
| Schlumberger, M | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Babur, M; Brabant, G; Burrows, N; Mejin, M; Resch, J; Ridsdale, S; Rowling, EJ; Williams, KJ | 1 |
| B Cohen, R; Olszanski, AJ; Patson, B | 1 |
| Bible, KC; Bieber, C; Bossou, AR; Burton, JK; Erlichman, C; Goh, BC; Harris, P; Isham, CR; Karlin, NJ; Kukla, AK; Kumar, P; Lim, WT; Maples, WJ; Menefee, ME; Molina, JR; Smallridge, RC; Suman, VJ; Traynor, AM; Webster, KP | 1 |
| Bible, KC; Bossou, AR; Copland, JA; Fisher, KE; Isham, CR; Kumar, R; Lingle, WL; Marlow, L; Negron, V; Sherman, EJ; Smallridge, RC; Suman, VJ | 1 |
10 review(s) available for indazoles and Thyroid Neoplasms
| Article | Year |
|---|---|
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
Topics: Anilides; Carcinoma, Neuroendocrine; Cardiotoxicity; Humans; Hypertension; Indazoles; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sulfonamides; Thyroid Neoplasms | 2018 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
Axitinib in the Treatment of Head and Neck Malignancies.
Topics: Axitinib; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Squamous Cell Carcinoma of Head and Neck; Survival; Thyroid Neoplasms | 2016 |
Neoadjuvant Therapy in Differentiated Thyroid Cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Humans; Indazoles; Japan; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Slovenia; Sorafenib; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2016 |
Tyrosine kinase inhibitors and the thyroid.
Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms | 2009 |
Axitinib (AG-013736).
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Biological Availability; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Imidazoles; Indazoles; Neoplasms; Pancreatic Neoplasms; Thyroid Neoplasms | 2010 |
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Pharmacokinetic evaluation of axitinib.
Topics: Animals; Axitinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Pancreatic Neoplasms; Protein Kinase Inhibitors; Thyroid Neoplasms | 2012 |
Early clinical studies of novel therapies for thyroid cancers.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2008 |
9 trial(s) available for indazoles and Thyroid Neoplasms
| Article | Year |
|---|---|
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Indazoles; Iodine Radioisotopes; Male; Middle Aged; Pyrimidines; Sulfonamides; Thyroid Neoplasms; Treatment Failure | 2021 |
A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Indazoles; Iodine Radioisotopes; Male; Middle Aged; Pyrimidines; Sulfonamides; Thyroid Neoplasms | 2017 |
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Pyrimidinones; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2019 |
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Medullary; Disease Progression; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2014 |
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quality of Life; Thyroid Neoplasms; Treatment Outcome | 2014 |
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
Topics: Adult; Aged, 80 and over; Antineoplastic Agents; Axitinib; Disease-Free Survival; Follow-Up Studies; Humans; Imidazoles; Indazoles; Middle Aged; Protein Kinase Inhibitors; Survival Rate; Thyroid Neoplasms; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms | 2008 |
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Cell Differentiation; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Iodine Radioisotopes; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Radiography; Radiopharmaceuticals; Sulfonamides; Thyroid Neoplasms; Time Factors; Treatment Failure; United States; Young Adult | 2010 |
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.
Topics: Aged; Animals; Disease Progression; Disease-Free Survival; Endpoint Determination; Female; Humans; Indazoles; Male; Mice; Mice, Nude; Middle Aged; Pyrimidines; Sulfonamides; Survival Analysis; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2012 |
21 other study(ies) available for indazoles and Thyroid Neoplasms
| Article | Year |
|---|---|
Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Dose-Response Relationship, Radiation; Doxorubicin; Female; Follow-Up Studies; Humans; Indazoles; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Pyrimidines; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms; Thyroidectomy; Tumor Burden | 2020 |
Heat Shock Protein 90 Inhibitors AUY922, BIIB021 and SNX5422 Induce Bim-mediated Death of Thyroid Carcinoma Cells.
Topics: Adenine; Apoptosis; Bcl-2-Like Protein 11; Benzamides; Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Glycine; HSP90 Heat-Shock Proteins; Humans; Indazoles; Isoxazoles; Proto-Oncogene Proteins c-akt; Pyridines; Resorcinols; Signal Transduction; Thyroid Neoplasms | 2020 |
Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Imidazoles; Indazoles; MAP Kinase Signaling System; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Oximes; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With
Topics: Adult; Anilides; Benzamides; Drug Resistance, Neoplasm; ETS Translocation Variant 6 Protein; Gene Fusion; Humans; Indazoles; Male; Mutation; Proto-Oncogene Proteins c-ets; Pyridines; Receptor, trkC; Repressor Proteins; Thyroid Neoplasms; Treatment Outcome | 2021 |
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Neuroendocrine; Female; Humans; Imidazoles; Indazoles; Iodine Radioisotopes; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Retrospective Studies; Spain; Thyroid Neoplasms; Treatment Outcome | 2017 |
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate; Thyroid Neoplasms; Treatment Outcome | 2018 |
A Case Report of Metastatic Primary Thyroid Leiomyosarcoma Treated with Pazopanib.
Topics: Aged; Antineoplastic Agents; Female; Humans; Indazoles; Leiomyosarcoma; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Thyroid Neoplasms | 2018 |
Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Indazoles; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Radiotherapy, Intensity-Modulated; Sorafenib; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2018 |
Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Carcinoma; Carcinoma, Papillary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Humans; Indazoles; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and Hypoxia-inducible factor-1 activity.
Topics: Animals; Cell Line, Tumor; Cell Movement; Female; Humans; Hypoxia-Inducible Factor 1; Indazoles; Mice; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; rho GTP-Binding Proteins; Signal Transduction; Sulfonamides; Thyroid Neoplasms | 2013 |
Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.
Topics: Animals; Carcinoma; Carcinoma, Papillary; Cell Culture Techniques; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; Humans; Indazoles; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Axitinib: VEGF inhibition in advanced thyroid cancer.
Topics: Axitinib; Humans; Imidazoles; Indazoles; Protein Kinase Inhibitors; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2014 |
Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Class I Phosphatidylinositol 3-Kinases; DNA Copy Number Variations; DNA Mutational Analysis; Drug Screening Assays, Antitumor; Female; Gene Amplification; Genetic Association Studies; Humans; Imidazoles; Indazoles; Iodine Radioisotopes; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Radiation Tolerance; Radiopharmaceuticals; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2015 |
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System.
Topics: Aged; Antineoplastic Agents; Arteries; Blood Pressure; Carcinoma, Renal Cell; Female; Heart; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pulse Wave Analysis; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; Vascular Stiffness | 2016 |
The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Synergism; Glycine; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Indazoles; Phosphorylation; Proto-Oncogene Proteins c-akt; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Vorinostat | 2016 |
Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Indazoles; MAP Kinase Signaling System; Mice, Nude; Pyridones; Pyrimidines; Pyrimidinones; Sulfonamides; Thyroid Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas.
Topics: Animals; Carcinoma; Carcinoma, Papillary; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Radiation; Enzyme Activation; Female; Histones; Humans; Hypoxia; Indazoles; Mice; Mice, Nude; Neoplasm Transplantation; Oxygen; Phosphatidylinositol 3-Kinases; Radiation Tolerance; Signal Transduction; Sulfonamides; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.
Topics: Adenoma, Oxyphilic; Adult; Black or African American; Female; Hair; Humans; Hypopigmentation; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Skin; Sulfonamides; Thyroid Neoplasms | 2010 |
Kinase inhibitors for refractory thyroid cancers.
Topics: Antineoplastic Agents; Cell Differentiation; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Humans; Indazoles; Multicenter Studies as Topic; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Thyroid Neoplasms; Time Factors; Treatment Outcome | 2010 |
GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Hypoxia; Cell Movement; Cell Proliferation; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mice; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Signal Transduction; Sulfonamides; Thyroid Neoplasms; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2011 |
Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Separation; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Indazoles; Mice; Mice, Nude; Mitosis; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Protein Serine-Threonine Kinases; Pyrimidines; RNA, Small Interfering; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Tubulin Modulators | 2013 |